Pharmacyclics
Showing 1 - 25 of 110
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Small Lymphocytic Lymphoma
- (no location specified)
Jul 19, 2023
Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in
Active, not recruiting
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 20, 2023
Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)
Completed
- Waldenstrom's Macroglobulinemia
-
Boston, Massachusetts
- +1 more
Dec 5, 2022
T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma Trial in New York, Columbus (Ibrutinib)
Active, not recruiting
- T-cell Lymphoma
- Relapsed and Refractory T-cell Lymphoma
-
New York, New York
- +1 more
Nov 8, 2022
Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),
Active, not recruiting
- Head and Neck Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Ibrutinib 560mg PO daily (Imbruvica)
- +2 more
-
La Jolla, CaliforniaUCSD Moores Cancer Center
Jan 11, 2023
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)
Active, not recruiting
- Waldenstrom Macroglobulinemia
- MYD88 Gene Mutation
-
Boston, Massachusetts
- +1 more
Apr 1, 2022
Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)
Recruiting
- Refractory Follicular Lymphoma
- Relapsed Follicular Lymphoma
-
Washington, District of Columbia
- +2 more
Jul 6, 2022
Breast Tumors, Malignant Tumor of Breast Trial in Dallas (Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg)
Recruiting
- Breast Neoplasms
- Malignant Neoplasm of Breast
- Trastuzumab
- +3 more
-
Dallas, Texas10 sites incl TX, WA, VA, and NV
May 16, 2022
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)
Not yet recruiting
- Lymphoma, Mantle-Cell
- +7 more
- Zilovertamab
- +2 more
- (no location specified)
Jun 21, 2022
Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Sacramento (Ibrutinib, Nivolumab)
Completed
- Metastatic Renal Cell Cancer
- Stage IV Renal Cell Cancer
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Feb 8, 2022
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in
Recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +5 more
- Ibrutinib
- +2 more
-
Fresno, California
- +2 more
Jan 24, 2023
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome Trial in United
Completed
- Chronic Myelomonocytic Leukemia
- +4 more
-
Los Angeles, California
- +4 more
Oct 5, 2022
Lung Cancer Trial in Houston (Ibrutinib)
Completed
- Lung Cancer
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 21, 2021
Chronic Lymphocytic Leukemia, Leukemia Trial in United States (Ibrutinib, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Leukemia
- Ibrutinib
- +3 more
-
Coral Gables, Florida
- +8 more
Sep 28, 2022
Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome Trial in
Completed
- Myelodysplastic Syndrome
- +4 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 11, 2021
Metastatic Solid Tumors Trial in San Francisco (PZP115891, PCI-24781)
Recruiting
- Metastatic Solid Tumors
- PZP115891, PCI-24781
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 23, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (biological, drug, other)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 24, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in La Jolla (Venetoclax, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
-
La Jolla, CaliforniaUC San Diego Moores Cancer Center
May 6, 2021
Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic
Withdrawn
- CLL
- +4 more
- Treatment Free Observation
-
Basking Ridge, New Jersey
- +8 more
Mar 4, 2022
High Risk Smoldering Multiple Myeloma Trial in New York (Ibrutinib)
Terminated
- High Risk Smoldering Multiple Myeloma
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Nov 18, 2020